Elderly autoimmune diseases
Conditions
Interventions
SLE subjects:N/A
RA subjects:N/A
SV subjects:N/A
Healthy control group:N/A
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1)Age: 18-65 years, patients with SLE or RA; (2)The diagnosis of SLE patients should meet the 1987 revised American College of Rheumatology classification criteria; disease activity was assessed using the systemic lupus erythematosus disease activity index (SLEDAI) scoring system; SLEDA score >= 5 , ANA antibody >= 1:40; hormone maintenance dose 28 mm/h; methotrexate or methotrexate + leflunomide treatment was ineffective for 3 months, and no other anti-rheumatic drugs (available low-dose hormones ± NSAIDs) were used in the last 3 months; (4)All patients have not been treated with glucocorticoids, immunosuppressants, disease-modifying antirheumatic drugs or biologics within 6 months; (5) The healthy control population should be sex- and age-matched to SLE or RA patients, and the enrolled population should have no history of SLE, RA or other AIDs.
Exclusion criteria
Exclusion criteria: (1)Patients or healthy controls taking antibiotics, anticonvulsant medications or suffering from gastrointestinal-type colds that affect the intestinal flora in the last month; (2)Patients or healthy controls with recent serious underlying diseases such as infectious diseases, malignancies, leukemia, acute heart failure, acute coronary syndrome; (3)Patients with signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric or cerebral diseases; (4)Patients who have undergone organ transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lymphocyte subsets;Blood ELISA cytokine levels;PBMC Immune Cell Types;Types of PBMC immune cells;Peripheral blood proteomics;Peripheral Blood RNA Sequencing;Peripheral blood single cell sequencing;Renal tissue proteomics;RNA sequencing of kidney tissue;Single cell sequencing of kidney tissue;Joint cavity synovial fluid routine;Synovial fluid biochemistry of joint cavity;Inflammatory index of synovial fluid;Joint cavity synovial proteomics;Joint synovial RNA sequencing;Single cell sequencing of synovial joint cavity;Skin tissue proteomics;Skin tissue RNA sequencing;Single Cell Sequencing of Skin Tissue;Blood routine test;Blood biochemical test;Routine detection of feces;Routine urine test;Vasculitis screening test;Immunoglobulin;24h urine protein;Inflammatory markers;C3?C4; | — |
Secondary
| Measure | Time frame |
|---|---|
| Antinuclear antibodies spectrum;Autoantibodies;Coagulation function;Joint imaging examination;Renal ultrasonography; | — |
Countries
China
Contacts
Public ContactPing Li
Chinese PLA General Hospital
Outcome results
None listed